USFDA Clearance For Pre Approval Inspection At Ahmedabad Site

21 Apr 2026 CW Team

The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI.

The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting.

Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.

The company has received the Establishment Inspection Report and an approval letter from the United States Food and Drug Administration (USFDA) following a Pre-Approval Inspection at its special economic zone (SEZ) oncology injectable manufacturing facility in SEZ1, Ahmedabad. The clearance relates to a new isolator injectable line and was disclosed in a filing dated 16 April, 2026. The inspection took place from fourth to 13th November, 2025 and resulted in documentation that the company said it had received. The organisation submitted the notice in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and asked that the information be brought to the attention of members of the exchange and the investing public. The disclosure highlighted the receipt of the Establishment Inspection Report, commonly abbreviated to EIR, and the approval letter for the Pre-Approval Inspection, commonly abbreviated to PAI. The SEZ oncology injectable manufacturing site, hereafter the site, will be referenced by its acronym in subsequent communications. The company indicated that the inspection related specifically to the newly authorised isolator injectable line and provided the dates of the audit for record and compliance purposes. The disclosure did not include further operational detail beyond the scope of the inspection report and approval. The company said existing quality systems will govern the integration of the new line into routine operations and timely reporting. Regulatory acknowledgement from the USFDA for the PAI represents a procedural milestone in the company's efforts to finalise commissioning of the line, the company added. The organisation confirmed it will adhere to listing and disclosure norms and will update stakeholders as appropriate through established channels. The company noted that regulatory records and correspondence will be maintained for audit and compliance purposes. Stakeholder communications will be issued through official regulatory filings and stock exchange disclosures.

Products

19 Jun 2026

REHAU Opens Interior Solutions Experience Centre in Gurgaon

REHAU Kitchen has partnered with Third Space Collective to launch a new experience centre in Gurgaon, strengthening its presence in India's growing premium interiors market.Spread across 3,400 sq. ft., the facility showcases a range of interior applications including kitchens, wardrobes, TV units, bar units and storage solutions, offering homeowners, architects and interior designers an opportunity to explore engineered interior products and material innovations under one roof.The collaboration is aimed at making advanced interior solutions more accessible while addressing growing consumer dem..

Resources

19 Jun 2026

Sky City Mall Marks Father's Day with Digital Film

Sky City Mall, Oberoi Realty's newest retail destination, has launched a Father's Day digital film that celebrates the bond between fathers and their children while highlighting the evolving role of malls as experience-led destinations.The campaign reflects the growing importance of retail destinations as spaces where shopping, dining, entertainment and social interactions come together to create memorable experiences for families. Through the film, Sky City Mall positions itself as a venue for meaningful moments and celebrations beyond traditional retail activity.The narrative follows a fathe..

Real Estate

19 Jun 2026

YKK India to Set Up Manufacturing Facility at Origins Chennai

Mahindra Industrial Park Chennai Limited (MIPCL), a joint venture between Mahindra World City Developers and Sumitomo Corporation of Japan, has announced that YKK India will establish a new manufacturing facility at Origins by Mahindra, Chennai.According to YKK India, the proposed facility will be its third manufacturing plant in the country and will span approximately 149,936 sq. m. The company plans to invest US$150 million in the project, which is expected to be completed by February 2028.YKK India, a manufacturer of fastening products serving the apparel, textile and industrial sectors, wi..